The Potential Role for Early Biomarker Testing as Part of a Modern, Multidisciplinary Approach to Sjögren’s Syndrome Diagnosis

Beckman, Kenneth A.; Luchs, Jodi; Milner, Mark S.; Ambrus, Julian L.

doi:10.1007/s12325-017-0501-3

Cited by 32 publications

(18 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There may also be many unreported cases. Many cases of SS are believed to “impact daily living.” Early detection and early treatment are pertinent for better outcomes, including curbing the progressive symptoms (Beckman, Luchs, Milner, & Ambrus, ; Means et al, ). It can be still disputable to consider whether ranulas may be an early detectable sign of SS.…”

Section: Discussionmentioning

confidence: 99%

Sjögren’s syndrome and ranula development

et al. 2019

View full text Add to dashboard Cite

Objectives We hypothesized that the extravasation of saliva from damaged ducts with lymphocytic infiltration in patients with Sjögren's syndrome causes ranulas. There are too many uncertainties to support this hypothesis. The aim of this study was to investigate whether there is an association between Sjögren's syndrome and ranulas. Materials and Methods We observed three cases of patients with ranulas who were also diagnosed with Sjögren's syndrome at the same facility. These cases led to the question of whether there are other such cases, and thus, an exhaustive literature search was conducted. Results Three cases in two case reports of mucocele of the floor of the mouth associated with adult Sjögren's syndrome were noted. Including our cases, until now, there have been six cases of ranula with adult Sjögren's syndrome. Conclusions It could be useful to investigate whether patients presenting with a ranula are also affected by Sjögren's syndrome and, conversely, investigate patients with Sjögren's syndrome longitudinally to see whether they develop ranulas.

show abstract

Section: Discussionmentioning

confidence: 99%

Sjögren’s syndrome and ranula development

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The authors recommend the performance of a labial gland biopsy in the diagnostic evaluation of patients with weakly positive anti-SSA or anti-SSB antibodies (or anti-SSB alone), in whom SS is suspected.A commercial assay for three murine tissue specific autoantibodies, carbonic anhydrase 6, parotid specific protein, and salivary protein-1, is now available as a test for early Sjögren's syndrome. However, the ability of these antibodies to mark individuals who are destined to develop Sjögren's syndrome has not been validated [57]. Labial gland biopsy performance and interpretation.…”

Section: Diagnosis Of Sjögren Syndromementioning

confidence: 99%

Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults

Baer

Walitt

2018

Rheumatic Disease Clinics of North America

View full text Add to dashboard Cite

Dry eye and dry mouth symptoms are each reported by up to 30% of persons more than 65 years of age, particularly in women. Medication side effects are the most common contributing factors. The evaluation of these symptoms requires measures of ocular and oral dryness. Sjögren syndrome is the prototypical disease associated with dryness of the eyes and mouth and predominantly affects women in their perimenopausal and postmenopausal years. In addition to topical treatment of the mucosal dryness, patients with Sjögren syndrome may require treatment with systemic immunomodulatory and immunosuppressive agents to manage a variety of extraglandular manifestations.

show abstract

“…In this disease, the immune state appears mediated by T cells and excessive activation of B lymphocytes with the generation of autoantibodies such as anti-Ro/60 and anti-La/SSB, directed towards nuclear antigens. In addition, in the more common secondary SS form, associated with other rheumatic autoimmune diseases, there is an infiltration of immune cells in various organs, such as endocrine glands, and deposition of various autoantibodies including rheumatoid factor (RF), anti-Ro60/SS-A and anti-La/SS-B, which provoke inflammation mediated by pro-inflammatory cytokines [ 9 ]. Antibodies to Ro60 antigens are called anti-SSA/Ro and patients who express Ro60 antibodies in most cases are diagnosed with autoimmune conditions, including SS.…”

Section: Introductionmentioning

confidence: 99%

Advances in Mast Cell Activation by IL-1 and IL-33 in Sjögren’s Syndrome: Promising Inhibitory Effect of IL-37

Conti

Stellin

Caraffa

et al. 2020

IJMS

View full text Add to dashboard Cite

Sjögren’s syndrome (SS) is a chronic autoimmune inflammatory disease that affects primarily older women and is characterized by irreversible damage of the exocrine glands, including tear (xerophthalmia) and salivary glands (xerostomia). Secretory glands lose their functionality due to the infiltration of immune cells, which produce cytokines and cause inflammation. Primary SS is characterized by dry syndrome with or without systemic commitment in the absence of other pathologies. Secondary SS is accompanied by other autoimmune diseases with high activation of B lymphocytes and the production of autoantibodies, including the rheumatoid factor. Other cells, such as CD4+ T cells and mast cells (MCs), participate in SS inflammation. MCs are ubiquitous, but are primarily located close to blood vessels and nerves and can be activated early in autoimmune diseases to express a wide variety of cytokines and chemokines. In the SS acute phase, MCs react by generating chemical mediators of inflammation, tumor necrosis factor (TNF), and other pro-inflammatory cytokines such as interleukin (IL)-1 and IL-33. IL-33 is the specific ligand for ST2 capable of inducing some adaptive immunity TH2 cytokines but also has pro-inflammatory properties. IL-33 causes impressive pathological changes and inflammatory cell infiltration. IL-1 family members can have paracrine and autocrine effects by exacerbating autoimmune inflammation. IL-37 is an IL-1 family cytokine that binds IL-18Rα receptor and/or Toll-like Receptor (TLR)4, exerting an anti-inflammatory action. IL-37 is a natural inhibitor of innate and acquired immunity, and the level is abnormal in patients with autoimmune disorders. After TLR ligand activation, IL-37 mRNA is generated in the cytoplasm, with the production of pro-IL-37 and later mature IL-37 caspase-1 mediated; both precursor and mature IL-37 are biologically active. Here, we discuss, for the first time, the current knowledge of IL-37 in autoimmune disease SS and propose a new therapeutic role.

show abstract

The Potential Role for Early Biomarker Testing as Part of a Modern, Multidisciplinary Approach to Sjögren’s Syndrome Diagnosis

Cited by 32 publications

References 63 publications

Sjögren’s syndrome and ranula development

Sjögren’s syndrome and ranula development

Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults

Advances in Mast Cell Activation by IL-1 and IL-33 in Sjögren’s Syndrome: Promising Inhibitory Effect of IL-37

Contact Info

Product

Resources

About